recombinate süstelahuse pulber ja lahusti
baxter ag - viii hüübimisfaktor - süstelahuse pulber ja lahusti - 500rÜ 10ml 10ml 1tk
dotagita süstelahus
agfa healthcare imaging agents gmbh - gadoteerhape - süstelahus - 279,32mg 1ml 5ml 1tk; 279,32mg 1ml 10ml 10tk; 279,32mg 1ml 60ml 10tk; 279,32mg 1ml 15ml 1tk; 279,32mg 1ml 20ml 10tk; 279,32mg 1ml 60ml 1tk
recombinate süstelahuse pulber ja lahusti
baxter ag - viii hüübimisfaktor - süstelahuse pulber ja lahusti - 250rÜ 10ml 10ml 1tk
recombinate süstelahuse pulber ja lahusti
baxter ag - viii hüübimisfaktor - süstelahuse pulber ja lahusti - 1000rÜ 10ml 10ml 1tk
dotarem (mitmeannuseline) süstelahus
guerbet - gadoteerhape - süstelahus - 0,5mmol 1ml 60ml 1tk
qutavina
eurogenerics holdings b.v. - teriparatiid - osteoporoos - kaltsiumi homöostaas - qutavina is indicated in adults. osteoporoosi ravi postmenopausis naistel ja meestel, kellel on suurem luumurdude risk. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. ravi osteoporoosi seostatakse pidevat süsteemset glükokortikoidi ravi naiste ja meeste suurenenud risk luumurdude.
heplisav b
dynavax gmbh - hepatiit b pinnaantigeen - b-hepatiit - vaktsiinid - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.
dotascan süstelahus
farmak international sp. z o.o. - gadoteerhape - süstelahus - 0,5mmol 1ml 60ml 10tk; 0,5mmol 1ml 100ml 1tk; 0,5mmol 1ml 5ml 10tk; 0,5mmol 1ml 10ml 1tk; 0,5mmol 1ml 15ml 1tk; 0,5mmol 1ml 20ml 1tk; 0,5mmol 1ml 100ml 10tk; 0,5mmol 1ml 15ml 10tk; 0,5mmol 1ml 10ml 10tk
paxlovid
pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.
krystexxa
crealta pharmaceuticals ireland limited - peglotiaas - podagra - antigude preparaadid - krystexxa on näidustatud raske kroonilise tophaceous kurnav podagra täiskasvanud, kes võib olla erodeeriv foorumi ja normaliseerida ksantiini oksüdaasi inhibiitoritega maksimaalse oli meditsiiniliselt ei allunud annuse korral või kelle jaoks nende ravimitega on vastunäidustatud.